Computer simulation of systemic circulation and clot lysis dynamics during thrombolytic therapy that accounts for inner clot transport and reaction

Circulation

Volumn 94, Issue 4, 1996, Pages 763-774

  Anand, Sriram ^a   Diamond, Scott L ^a  

^a the State University of New York   (United States)

Author keywords

fibrinolysis; hemodynamics; pharmacokinetics; plasminogen activators; thrombolysis

Indexed keywords

ALTEPLASE; ANTIPLASMIN; MACROGLOBULIN; PLASMINOGEN; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ARTICLE; BLOOD CLOT LYSIS; COMPARTMENT MODEL; COMPUTER SIMULATION; FIBRIN CLOT; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0029763116     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.4.763     Document Type: Article

References (60)

1. Blinc A, Planinsic G, Keber D, Jarh O, Lahajnar G, Zidansek A, Demsar F. Dependence of blood clot lysis on the mode of transport of urokinase into the clot: a magnetic resonance imaging study in vitro. Thromb Haemost. 1991;65:549-552.
2. Blinc A, Keber D, Lahajnar G, Stegnar M, Zidansek A, Demsar F. Lysing patterns of retracted blood clots with diffusion or bulk flow transport of plasma with urokinase into clots: a magnetic resonance imaging study in vitro. Thromb Haemost. 1992;68:667-671.
3. Wu JH, Siddiqui K, Diamond SL. Transport phenomena and clot dissolution therapy: an experimental investigation of diffusion-controlled and permeation-enhanced fibrinolysis. Thromb Haemost. 1994;72:105-112.
4. Diamond SL, Anand S. Inner clot diffusion and permeation during fibrinolysis. Biophys J. 1993;65:2622-2643.
5. Anand S, Wu JH, Diamond SL. Enzyme-mediated proteolysis of fibrous biopolymers: dissolution front movement in fibrin and collagen under conditions of diffusive and convective transport. Biotech Bioeng. 1995;48:89-107.
6. Garber PJ, Mathieson AL, Ducas J, Patton JN, Geddes JS, Prewitt RM. Thrombolytic therapy in cardiogenic shock: effect of increased aortic pressure and rapid tPA administration. Can J Cardiol. 1995;11:30-36.
7. Prewitt RM, Gu S, Garber PJ, Ducas J. Marked systemic hypotension depresses coronary thrombolysis induced by intracoronary administration of recombinant tissue-type plasminogen activator. J Am Coll Cardiol. 1992;20:1626-1633.
8. Prewitt RM, Gu S, Schick U, Ducas J. Intraaortic balloon counter-pulsation enhances coronary thrombolysis induced by intraveneous administration of a thrombolytic agent. J Am Coll Cardiol. 1994;23:794-798.
9. Miller RD, Burchell HB, Edwards JE. Myocardial infarction with and without acute coronary occlusion: a pathological study. Arch Intern Med. 1951;88:597-611.
10. Zidansek A, Blinc A. The influence of transport parameters and enzyme kinetics of the fibrinolytic system thrombolysis: mathematical modeling of two idealized cases. Thromb Haemost. 1991;65:553-559.
11. Tiefenbrunn AJ, Graor RA, Robison AK, Lucas FV, Hotchkiss A, Sobel BE. Pharmacodynamics of tissue plasminogen activator characterized by computer-assisted simulation. Circulation. 1986;73:1291-1299.
12. Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. J Biol Chem. 1982;257:2912-2919.
13. Tebbe U, Tanswell P, Seifried E, Feuerer W, Scholz KH, Herrman KS. Single bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarction. Am J Cardiol. 1989;64:448-453.
14. Kohler M, Sen S, Miyashita C, Hermes R, Pindur G, Heiden M, Berg G, Morsdorf S, Leipnitz, Zeppezauer M, Schieffer H, Wenzel E, Schonberger A, Hollemeyer K. Half-life of single chain urokinase-type plasminogen activator (scu-PA) and two-chain urokinase-type plasminogen activator (tcu-PA) in patients with acute myocardial infarction. Thromb Res. 1991;62:75-81.
15. Park IH, Johnson CS, Jones MR, Gabriel DA. Probes of fibrin gel porosity. In: Mosesson MW, Amrani DL, Siebenlist KR, DiOrio JP, eds. Fibrinogen and Biochemistry: Biological Functions. Gene Regulation and Expression. Amsterdam, Netherlands: Excerpta Medica; 1988:123-128.
16. Matveyev MY, Domogatsky SP. Penetration of macromolecules into contracted blood clots. Biophys J. 1992;63:862-863.
17. Sahimi M, Hughes BD, Scriven LE, Davis HT. Dispersion in flow through porous media: one-phase flow. Chem Eng Sci. 1986;41:2103-2122.
18. Dullien FA. Porous Media: Fluid Transport and Pore Structure. New York, NY: Academic Press; 1979.
19. Ranby M, Brandstrom A. Control of t-PA mediated fibrinolysis. In: Kluft C, ed. Tissue-Type Plasminogen Activator (t-PA). Boca Raton, Fla: CRC Press; 1988:211-224.
20. Gemmill JD, Hogg KJ, MacIntyre PD, Booth N, Rae AP, Dunn FG, Hillis WS. A pilot study of the efficacy and safety of bolus administration of alteplase in acute myocardial infarction. Br Heart J. 1991;66:134-138.
21. Mueller HS, Rao AK, Forman SA, and the TIMI Investigators. Thrombolysis in Myocardial Infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinolysis with two forms of recombinant tissue-type plasminogen activator. J Am Coll Cardiol. 1987;10:479-490.
22. Noe DA, Bell WR. A kinetic analysis of fibrinolysis during plasminogen activator therapy. Clin Pharm Ther. 1987;41:297-303.
23. Collen D, Bounameaux H, DeCock F, Lijnen HR, Verstraete M. Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. Circulation. 1986;73:511-518.
24. Lucas MA, Fretto LJ, McKee PA. The binding of human plasminogen to fibrin and fibrinogen. J Biol Chem. 1983;258:4249-4256.
25. Thurston GB, Henderson NM. Impedance of a fibrin clot in a cylindrical tube: relation to clot permeability and viscoelasticity. Biorheology. 1995;32:503-520.
26. Potter van Loon BJ, Rijken DC, Brommer EJP, van der Maas APC. The amount of plasminogen, tissue-type plasminogen activator, and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility. Thromb Haemost. 1992;67:101-105.
27. Wall TC, Califf RM, George BS, Ellis SG, Samaha J, Kereiakes DJ, Worley SJ, Sigmon K, Topol EJ, for the TAMI-7 Study Group. Accelerated plasminogen activator dose regimens for coronary thrombolysis. J Am Coll Cardiol. 1992;19:482-489.
28. Le vine MN. Bolus, front-loaded, and accelerated thrombolytic infusions for myocardial infarction and pulmonary embolism. Chest. 1991;99:128S-134S.
29. Zidansek A, Blinc A, Lahajnar G, Keber D, Blinc R. Finger-like lysing patterns of blood clots. Biophys J. 1995;69:803-809.
30. Anand S, Diamond SL. Simulations of systemic circulation dynamics and consequent thrombi dissolution rates during intravenous thrombolytic therapy. American Institute of Chemical Engineering 1995 Annual Meeting, November 13, 1995, 478. Abstract.
31. Blinc A, Kennedy SD, Bryant G, Marder VJ, Francis CW. Flow through clots determines the rate and pattern of fibrinolysis. Thromb Haemost. 1994;71:230-235.
32. Moschos CB, Oldewurtel HA, Haider B, Regan TJ. Effect of coronary thrombus age on fibrinogen uptake. Circulation. 1976;54:653-656.
33. Prewitt RM. Thrombolytic therapy in patients where hypotension and cardiogenic shock complicate acute myocardial infarction. Can J Cardiol. 1993;9:155-157.
34. Prewitt RM, Gu SA, Greenberg D, Chan SM, Schick U, LaPointe H, Ducas J. Effects of flow on recombinant tissue plasminogen activator-induced pulmonary thrombolysis. J Appl Physiol. 1991;71:1441-1446.
35. Prewitt RM, Downes AM, Gu SA, Chan SM, Ducas J. Effects of hydralazine and increased cardiac output on recombinant tissue plasminogen activator-induced thrombolysis in canine pulmonary embolism. Chest. 1991;99:708-714.
36. Prewitt RM, Gu S, Schick U, Wiens A, Ducas J. The effect of a moderate increase in a low coronary artery inflow pressure on coronary thrombolysis induced by intraveneous administration of recombinant tissue plasminogen activator. Thromb Haemost. 1993;69:1353. Abstract.
37. Francis CW, Onundarson PT, Carstensen EL, Blinc A, Meltzer RS, Schwarz K, Marder VJ. Enhancement of fibrinolysis in vitro by ultrasound. J Clin Invest. 1992;90:2063-2068.
38. Blinc A, Francis CW, Trudnowski JL, Carstensen EL. Characterization of ultrasound-potentiated fibrinolysis in vitro. Blood. 1993;81:2636-2643.
39. Siddiqi F, Blinc A, Braaten J, Francis CW. Ultrasound increases flow through fibrin gels. Thromb Haemost. 1995;73:495-502.
40. Harpaz D, Chen X, Francis CW, Marder VJ, Meltzer RS. Ultrasound enhancement of thrombolysis and reperfusion in vitro. J Am Coll Cardiol. 1993;21:1507-1511.
41. Mizuno K, Satomura K, Miyamoto A, Arakawa K, Shibuya T, Arai T, Kurita A, Nakamura H, Ambrose JA. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N Engl J Med. 1992;326:287-291.
42. Ambrose JA, Alexopoulos D. Thrombolysis in unstable angina: will the beneficial effects of thrombolytic therapy in myocardial infarction apply to patients with unstable angina? J Am Coll Cardiol. 1989;13:1661-1671.
43. Uchida Y, Masuo M, Tomaru T, Kato A, Sugimoto T. Fiberoptic observation of thrombosis and thrombolysis in isolated human coronary arteries. Am Heart J. 1986;112:691-696.
44. Hess H, Ingrisch H, Mietaschk T, Rath H. Local low-dose thrombolytic therapy of peripheral arterial occlusions. N Engl J Med. 1982;307:1627-1636.
45. McNamara TO, Fischer JR. Thrombolysis of peripheral arterial and graft occlusion. Am J Radiol. 1985;144:769-775.
46. Semba CP, Dake MD. Iliofemoral deep venous thrombosis: aggressive therapy with catheter-directed thrombolysis. Radiology. 1994;191:487-494.
47. Voter WA, Lucaveche C, Erickson HP. Concentration of protein in fibrin fibers and fibrinogen polymers determined by refractive index matching. Biopolymers. 1986;25:2375-2384.
48. Press WH, Teukolsky SA, Vetterling WT, Flannery BP. Numerical Recipes in C: The An of Scientific Computing. 2nd ed. Cambridge, UK: Cambridge University Press; 1992.
49. Booth NA, Robbie LA, Croll AM, Bennett B. Lysis of platelet-rich thrombi: the role of PAI-1. Ann N Y Acad Sci. 1992;667:70-80.
50. Brommer EJP, Potter van Loon, BJ, Rijken DC, Van Bockel JH. Composition and susceptibility to thrombolysis of pathological human arterial thrombi. Ann N Y Acad Sci. 1992;667:283-285.
51. Thorsen S, Mullertz S, Suenson E, Kok P. Sequence of formation of molecular forms of plasminogen and plasmin-inhibitor complexes in plasma activated by urokinase or tissue-type plasminogen activator. Eur J Biochem. 1984;223:179-187.
52. Husain SS, Hasan AAK, Budzynski AZ. Differences between binding of one-chain and two-chain tissue plasminogen activators to noncross-linked and cross-linked fibrin clots. Blood. 1989;74:999-1006.
53. Zamarron C, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by natural and recombinant tissue type plasminogen activator. J Biol Chem. 1984;259:2080-2093.
54. Collen D, Zamarron C, Lijnen HR, Hoylaerts M. Activation of plasminogen by pro-urokinase. J Biol Chem. 1986;261:1259-1266.
55. Lottenberg R, Christensen U, Jackson CM, Coleman PL. Assay of coagulation proteases using peptide chromogenic and fluorogenic substrates. Methods Enzymol. 1981;80:341-361.
56. Wu JH, Diamond SL. A fluorescence quench and dequench assay of fibrinogen polymerization, fibrinogenolysis, and fibrinolysis. Anal Biochem. 1995;224:83-91.
57. Wiman B, Collen D. On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem. 1978;84:573-578.
58. 2-macroglobulin. J Biol Chem. 1984;259:8870-8878.
59. Lijnen HR, Van Hoef B, Collen D. On the reversible interaction of plasminogen activator inhibitor-1 with tissue-type plasminogen activator and with urokinase-type plasminogen activator. J Biol Chem. 1991;266:4041-4044.
60. Wiman B, Lijnen HR, Collen D. On the specific interaction between the lysine-binding sites in plasmin and complementary sites in a2-antiplasmin and in fibrinogen. Biochim Biophys Acta. 1979;579:142-154.